目的 前瞻性观察缬沙坦与厄贝沙坦对糖尿病肾病患者微量尿白蛋白及血压的影响.方法 前瞻性观察106例2型糖尿病肾病患者,按数字表法将患者随机分为A、B两组,均采用相应的基础降糖治疗后,A组(n=51)患者加用缬沙坦80 mg/d,B组患者(n=55)用厄贝沙坦150 mg/d,12周为1个疗程,每疗程观察微量白蛋白尿及血压,共3个疗程.结果 ①缬沙坦及厄贝沙坦对微量尿白蛋白经3个疗程治疗后,差异有统计学意义(Z=-6.490,P<0.001).两种药物对于微量尿白蛋白治疗在各疗程终点比较差异无统计学意义(P>0.05).②缬沙坦及厄贝沙坦对血压经3个疗程治疗后差异有统计学意义(P<0.05).两种药物对于收缩压治疗在各疗程终点比较,差异有统计学意义(P<0.05).结论 两组药物均有减少糖尿病肾病患者微量蛋白尿及降压作用,而厄贝沙坦比缬沙坦在降低血压方面更有优势.%Objective This was a prospective observational sludy on effecls of valsarlan and irbesarlan in palienls with diabelic nephropalhy on Lrace urinary albumin and btood pressure. Methods A prospective observational study was conducted on 106 cases of type 2 diabetic patients with nephropalhy. The patients were randomly divided into two groups (A and B) , patients in group A (n =51) were treated with valsarlan 80 mg / d, those in group B (n = 55) were treated with irbesarlan 150 mg / d, for 12 weeks as a course, for each course of treatment, microalbuminuria, and btood pressure were measured for a total of three courses. Results ( 1) Valsarlan and irbesarlan groups' trace urinary albumin during three courses of treatment difference had statistically significant difference (Z = - 6. 490 P <0. 001). (2) The btood pressure of the two groups during the three courses of treatment was significantly different (P < 0. 05 ) ; in each course of treatment the systolic btood pressure was significantly different (P <0.05). Conclusion Both drugs could reduce microalbuminuria and had anlihypertensive effect in patients with diabelic nephropalhy, while irbesarlan was more effective in towering btood pressure as compared with valsarlan.
展开▼
